Kymera Therapeutics, Inc.
$88.84
▲
0.87%
2026-04-22 10:12:13
www.kymeratx.com
NGM: KYMR
Explore Kymera Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$7.31 B
Current Price
$88.84
52W High / Low
$103 / $24.43
Stock P/E
—
Book Value
$19.42
Dividend Yield
—
ROCE
-20.82%
ROE
-25.78%
Face Value
—
EPS
$-3.69
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
238
Beta
2.29
Debt / Equity
5.21
Current Ratio
10.47
Quick Ratio
10.47
Forward P/E
-21.22
Price / Sales
177.09
Enterprise Value
$6.18 B
EV / EBITDA
-18.23
EV / Revenue
157.55
Rating
Strong Buy
Target Price
$119.14
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Theriva Biologics, Inc. | $0.41 | — | $18.89 M | — | -85.21% | -1.38% | $1.5 / $0.16 | $0.43 |
| 2. | uniQure N.V. | $18.04 | — | $1.07 B | — | -24.65% | -2.07% | $71.5 / $8.73 | $3.19 |
| 3. | Processa Pharmaceuticals, Inc. | $2.71 | — | $8.25 M | — | -250.81% | -3.73% | $19.63 / $1.76 | $2.17 |
| 4. | Zentalis Pharmaceuticals, Inc. | $4.03 | — | $301.33 M | — | -57.45% | -49.54% | $6.95 / $1.13 | $3.13 |
| 5. | Xilio Therapeutics, Inc. | $8.45 | — | $49.46 M | — | -42.66% | -1.33% | $16.52 / $6.47 | $7.79 |
| 6. | BioMarin Pharmaceutical Inc. | $54.33 | 30.1 | $10.47 B | — | 5.99% | 5.94% | $66.28 / $50.76 | $31.65 |
| 7. | PepGen Inc. | $1.73 | — | $117.5 M | — | -58.05% | -67.39% | $7.8 / $1.01 | $2.14 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 2.87 M | 2.76 M | 11.48 M | 22.1 M | 7.39 M |
| Operating Profit | -97.9 M | -88.67 M | -84.56 M | -74.43 M | -80.75 M |
| Net Profit | -86.98 M | -82.17 M | -76.61 M | -65.58 M | -70.75 M |
| EPS in Rs | -1.07 | -1.01 | -0.94 | -0.8 | -0.87 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 39.21 M | 47.07 M | 78.59 M | 46.83 M |
| Operating Profit | -345.54 M | -256.71 M | -165.53 M | -161.26 M |
| Net Profit | -311.35 M | -223.86 M | -146.96 M | -154.81 M |
| EPS in Rs | -3.81 | -2.74 | -1.8 | -1.9 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 1.74 B | 978.03 M | 575.76 M | 603.13 M |
| Total Liabilities | 163.15 M | 142.42 M | 180.79 M | 112.98 M |
| Equity | 1.58 B | 835.62 M | 394.97 M | 490.15 M |
| Current Assets | 871.21 M | 510.27 M | 405.32 M | 419.42 M |
| Current Liabilities | 83.21 M | 67.77 M | 85.69 M | 71.34 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -232.89 M | -194.5 M | -102.83 M | -153.09 M |
| Investing CF | -521.06 M | -404.08 M | 139.89 M | 20.52 M |
| Financing CF | 990.71 M | 608.85 M | 4.19 M | 153 M |
| Free CF | -234.34 M | -207.34 M | -137.31 M | -155.92 M |
| Capex | -1.45 M | -12.84 M | -34.48 M | -2.84 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | -40.11% | 67.84% | — | — |
| Earnings Growth % | -52.32% | 5.07% | — | — |
| Profit Margin % | -475.57% | -186.99% | -330.6% | — |
| Operating Margin % | -545.36% | -210.62% | -344.37% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | -459.37% | -182.21% | -323.87% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.